The REMODEL trial testing semaglutide’s efficacy in patients with CKD and T2DM also employed MRI, transcriptomics, blood and urine samples, and kidney biopsies to clarify the drug’s effects.
For payers, the case for patient engagement in CKD is compelling. It improves outcomes, reduces costs, supports quality metrics and star ratings, and strengthens member satisfaction. But it doesn’t ...
These findings provide evidence of the relevance of markers of cardiometabolic health for dementia among adults in China, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback